中金:维持荣昌生物“跑赢行业”评级 升目标价至45港元

智通财经
02 May

公司公布1Q25业绩:收入5.26亿元,同比增长59.17%;归母净利润亏损2.54亿元,同比减亏接近1亿元,符合该行预期。中金发布研报称,基本维持荣昌生物(09995)2025年/2026年归母净利润预测亏损9.15亿元/亏损3.33亿元不变。由于泰它西普gMG数据超该行预期,有望打开该适应症的全球市场空间,基于DCF模型,该行维持公司跑赢行业评级,上调目标价40.6%至45港币,较当前股价有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10